ArticleJournal of cancer research and clinical oncology2009
Galectin-3 in urine of cancer patients: stage and tissue specificity.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis.International journal of molecular sciences · 2024Article
- Fecal and Urinary Adipokines as Disease Biomarkers.Biomedicines · 2023Review
- Review
- Structure-based identification of galectin-1 selective modulators in dietary food polyphenols: a pharmacoinformatics approach.Molecular diversity · 2022Article
- The Role of Galectins in Cervical Cancer Biology and Progression.BioMed research international · 2018Review
- Role of Galectin-3 Combined with Multi- Detector Contrast Enhanced Computed Tomography in Predicting Disease Recurrence in Patients with Ovarian CancerAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Antimetastatic pectic polysaccharide from Decalepis hamiltonii; galectin-3 inhibition and immune-modulation.Clinical & experimental metastasis · 2017Article
- Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia.Journal of pathology and translational medicine · 2015Review
- Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Journal of the American Heart Association · 2014Article
- Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.International journal of clinical oncology · 2011Article
- Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.BMC cancer · 2010Article
- Galectins as cancer biomarkers.Cancers · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGalectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy. EXPERIMENTAL
designUrine was collected from all types of cancer patients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3.
resultsCancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I-V, respectively, at P approximately <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy.
conclusionsSample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.